|
16 Jul 2025 |
Jyothy Labs
|
Consensus Share Price Target
|
350.30 |
416.92 |
- |
19.02 |
buy
|
|
|
|
|
27 May 2025
|
Jyothy Labs
|
Geojit BNP Paribas
|
350.30
|
404.00
|
341.50
(2.58%)
|
15.33 |
Accumulate
|
|
|
|
|
21 May 2025
|
Jyothy Labs
|
Sharekhan
|
350.30
|
395.00
|
338.75
(3.41%)
|
12.76 |
Buy
|
|
|
Q4FY25 was yet another muted quarter for JLL amid subdued demand and higher competitive intensity hit revenue growth, while inflation in key input prices impacted profitability.
|
|
12 May 2025
|
Jyothy Labs
|
Motilal Oswal
|
350.30
|
375.00
|
350.80
(-0.14%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported 1% YoY sales growth (below our est.) in 4QFY25. Volume growth was 4% (est. 7%, 8% in 3QFY25). The gap between volume and value growth was due to higher grammage and promotional price subs in select categories.
|
|
12 Apr 2025
|
Jyothy Labs
|
Axis Direct
|
350.30
|
405.00
|
371.50
(-5.71%)
|
15.62 |
Buy
|
|
|
We recommend a BUY with a near-term TP of Rs 405, implying an upside of 10% from the CMP.
|
|
11 Mar 2025
|
Jyothy Labs
|
Geojit BNP Paribas
|
350.30
|
395.00
|
333.90
(4.91%)
|
Target met |
Buy
|
|
|
|
|
01 Feb 2025
|
Jyothy Labs
|
Axis Direct
|
350.30
|
450.00
|
415.70
(-15.73%)
|
28.46 |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
31 Jan 2025
|
Jyothy Labs
|
Sharekhan
|
350.30
|
490.00
|
398.40
(-12.07%)
|
39.88 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q3FY25 performance was muted with revenue growing by just 4%, while a ~110 bps y-o-y decline in OPM led to 4% y-o-y decline in PAT.
|
|
04 Dec 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
350.30
|
496.00
|
411.15
(-14.80%)
|
41.59 |
Buy
|
|
|
|
|
13 Nov 2024
|
Jyothy Labs
|
Axis Direct
|
350.30
|
500.00
|
436.10
(-19.67%)
|
42.73 |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
12 Nov 2024
|
Jyothy Labs
|
Sharekhan
|
350.30
|
575.00
|
441.35
(-20.63%)
|
64.15 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q2FY2025 performance was muted with revenue and PAT remaining flat y-o-y. OPM at 18.9% rose by 38 bps y-o-y.
|
|
12 Nov 2024
|
Jyothy Labs
|
Motilal Oswal
|
350.30
|
500.00
|
441.35
(-20.63%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported flat sales YoY (miss) in 2QFY25. It posted a five-year CAGR of 10%. Volume growth was at 3%, on account of a high base.
|
|
13 Aug 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
350.30
|
645.00
|
548.10
(-36.09%)
|
84.13 |
Accumulate
|
|
|
|
|
26 Jul 2024
|
Jyothy Labs
|
Axis Direct
|
350.30
|
600.00
|
548.45
(-36.13%)
|
71.28 |
Buy
|
|
|
We maintain our long-term BUY rating on the stock.
|
|
25 Jul 2024
|
Jyothy Labs
|
Motilal Oswal
|
350.30
|
565.00
|
547.70
(-36.04%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported a revenue growth of 8% YoY (in line) in 1QFY25. It delivered a volume growth of 11% and continued to focus on volume-led growth to gain market share across categories.
|
|
25 Jul 2024
|
Jyothy Labs
|
Sharekhan
|
350.30
|
655.00
|
547.70
(-36.04%)
|
86.98 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q1FY2025 operating performance was in line with our expectation with revenues growing by 8% (versus expectation of 8.5%) while OPM stood at 18% (versus expectation of 17.9%).
|
|
25 Jul 2024
|
Jyothy Labs
|
ICICI Securities Limited
|
350.30
|
640.00
|
547.70
(-36.04%)
|
82.70 |
Buy
|
|
|
JYL’s Q1FY25 volume growth of 11% YoY is a material outperformance vs peers on a higher base as it continues to focus on direct distribution expansion, innovation, new SKUs coupled with continued investment behind the brands.
|
|
29 May 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
350.30
|
478.00
|
413.25
(-15.23%)
|
Target met |
Accumulate
|
|
|
|
|
16 May 2024
|
Jyothy Labs
|
Axis Direct
|
350.30
|
500.00
|
446.40
(-21.53%)
|
Target met |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
09 Mar 2024
|
Jyothy Labs
|
Axis Direct
|
350.30
|
475.00
|
429.50
(-18.44%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 475/share, implying an upside of 10% from the CMP.
|
|
23 Feb 2024
|
Jyothy Labs
|
Sharekhan
|
350.30
|
590.00
|
475.65
(-26.35%)
|
Target met |
Buy
|
|
|
|